Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
2.
Cell Oncol (Dordr) ; 46(2): 391-407, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36539575

ABSTRACT

PURPOSE: Despite recent advances, approximately 50% of patient with metastatic melanoma eventually succumb to the disease. Patients with melanomas harboring a BRAF mutation (BRAFMut) have a worse prognosis than those with wildtype (BRAFWT) tumors. Unexpectedly, interim AVAST-M Phase III trial data reported benefit from adjuvant anti-VEGF bevacizumab only in the BRAFMut group. We sought to find mechanisms underpinning this sensitivity. METHODS: We investigated this finding in vitro and in vivo using melanoma cell lines and clones generated by BRAFV600E knock-in on a BRAFWT background. RESULTS: Compared with BRAFWT cells, isogenic BRAFV600E clones secreted more VEGF and exhibited accelerated growth rates as spheroids and xenografts, which were more vascular and proliferative. Recapitulating AVAST-M findings, bevacizumab affected only BRAFV600E xenografts, inducing significant tumor growth delay, reduced vascularity and increased necrosis. We identified 814 differentially expressed genes in isogenic BRAFV600E/BRAFWT clones. Of 61 genes concordantly deregulated in clinical melanomas ROR2 was one of the most upregulated by BRAFV600E. ROR2 was shown to be RAF-MEK regulated in BRAFV600E cells and its depletion suppressed VEGF secretion down to BRAFWT levels. The ROR2 ligand WNT5A was also overexpressed in BRAFMut melanomas, and in ROR2-overexpressing BRAFV600E cells MEK inhibition downregulated WNT5A and VEGF secretion. CONCLUSIONS: These data implicate WNT5A-ROR2 in VEGF secretion, vascularity, adverse outcomes and bevacizumab sensitivity of BRAFMut melanomas, suggesting that this axis has potential therapeutic relevance.


Subject(s)
Melanoma , Proto-Oncogene Proteins B-raf , Receptor Tyrosine Kinase-like Orphan Receptors , Wnt-5a Protein , Humans , Bevacizumab/pharmacology , Bevacizumab/therapeutic use , Cell Line, Tumor , Melanoma/genetics , Melanoma/metabolism , Melanoma/pathology , Mitogen-Activated Protein Kinase Kinases/genetics , Mutation/genetics , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins B-raf/metabolism , Receptor Tyrosine Kinase-like Orphan Receptors/genetics , Wnt-5a Protein/genetics , Wnt-5a Protein/therapeutic use , Vascular Endothelial Growth Factor A/metabolism
3.
Clin Cancer Res ; 26(21): 5709-5719, 2020 11 01.
Article in English | MEDLINE | ID: mdl-33097493

ABSTRACT

PURPOSE: Angiogenesis is thought to be critical for tumor metastasis. However, inhibiting angiogenesis using antibodies such as bevacizumab (Avastin), has had little impact on melanoma patient survival. We have demonstrated that both angiogenesis and metastasis are increased in older individuals, and therefore sought to investigate whether there was an age-related difference in response to bevacizumab, and if so, what the underlying mechanism could be. EXPERIMENTAL DESIGN: We analyzed data from the AVAST-M trial of 1,343 patients with melanoma treated with bevacizumab to determine whether there is an age-dependent response to bevacizumab. We also examined the age-dependent expression of VEGF and its cognate receptors in patients with melanoma, while using syngeneic melanoma animal models to target VEGF in young versus old mice. We also examined the age-related proangiogenic factor secreted frizzled-related protein 2 (sFRP2) and whether it could modulate response to anti-VEGF therapy. RESULTS: We show that older patients respond poorly to bevacizumab, whereas younger patients show improvement in both disease-free survival and overall survival. We find that targeting VEGF does not ablate angiogenesis in an aged mouse model, while sFRP2 promotes angiogenesis in vitro and in young mice. Targeting sFRP2 in aged mice successfully ablates angiogenesis, while the effects of targeting VEGF in young mice can be overcome by increasing sFRP2. CONCLUSIONS: VEGF is decreased during aging, thereby reducing response to bevacizumab. Despite the decrease in VEGF, angiogenesis is increased because of an increase in sFRP2 in the aged tumor microenvironment. These results stress the importance of considering age as a factor for designing targeted therapies.


Subject(s)
Melanoma/genetics , Membrane Proteins/genetics , Neovascularization, Pathologic/genetics , Vascular Endothelial Growth Factor A/genetics , Age Factors , Aged , Aged, 80 and over , Animals , Bevacizumab/administration & dosage , Cell Line, Tumor , Disease-Free Survival , Gene Expression Regulation, Neoplastic/drug effects , Humans , Melanoma/drug therapy , Melanoma/pathology , Mice , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/pathology , Tumor Microenvironment/drug effects
5.
J Am Acad Dermatol ; 70(5): 927-33, 2014 May.
Article in English | MEDLINE | ID: mdl-24440319

ABSTRACT

BACKGROUND: Intralymphatic histiocytosis (IH) is a rare condition often associated with systemic disease. A benign condition, clinical presentations can vary greatly and its cause is largely unknown. Histologically, there are macrophages within distended lymphatic vessels, although this can be an incidental finding or the primary abnormality. OBJECTIVE: We present a series of 7 cases of IH with and without disease associations, and a review of the literature. We propose IH as either primary (without associated conditions) or secondary (associated with systemic disease). METHODS: This was a retrospective collection of patients whose skin biopsy specimens revealed intralymphatic collections of histiocytes. We reviewed their clinical presentation, disease associations, and staining of slides with CD68 in all cases, D2-40 in 5 cases, and HLA-DR in 4 cases. RESULTS: Clinical features were highly variable, and not all cases were associated with systemic disease. One case had admixed reactive angioendotheliomatosis. All 4 cases stained for HLA-DR showed strong expression by the intralymphatic macrophages. LIMITATIONS: Retrospective analysis and limited numbers are limitations. CONCLUSION: IH is not always associated with systemic disease although macrophage activation nevertheless implies immune activation.


Subject(s)
Histiocytosis/pathology , Lymphatic Vessels/pathology , Adult , Aged , Dilatation, Pathologic , Female , HLA-DR Antigens/metabolism , Histiocytosis/diagnosis , Histiocytosis/immunology , Histiocytosis/metabolism , Humans , Immunohistochemistry , Macrophage Activation , Male , Middle Aged , Retrospective Studies
7.
Peu ; 28(1): 15-20, ene.-mar. 2008. tab, ilus
Article in Spanish | IBECS | ID: ibc-81058

ABSTRACT

El artículo que se presenta a continuación quieredar a conocer la patología de las congelaciones através de un caso clínico. Además, pretende informara los profesionales de la salud de la actuaciónde los podólogos, bien sea en la fase preventiva,dando recomendaciones para evitarlas, en la fasecurativa, curando o compensando las secuelas.Proponemos un sencillo protocolo de prevenciónque incluye una exploración y estudio biomecánicodel pié, una revisión de las alteraciones de lapiel y de las uñas, consejos y revisión del calzadoy calcetines en base a la actividad a realizar. Comoconclusión podemos afirmar que la mejor manerade evitarlas es mentalizar e informar a todos loscolectivos expuestos(AU)


The next text get to know the frostbite patologyby a clinic case. Also, this report wants to informanother health professionals about the podiatricsactuations, in a preventive phase: giving heathcare,or in a recover phase: treating injuries andcompensating consequences. We propose an easyprevention protocol that’s includes: biomecanicstudy and exploration of the feet, skin and nailsdisorders, revision and care about footwear andsocks linked by the activity to do. Finishing, wewould to say that the best way to prevent it’s theinformation and to make abore all implicatedcollectives(AU)


Subject(s)
Humans , Female , Adult , Frostbite/epidemiology , Podiatry/methods , Frostbite/prevention & control , Biomechanical Phenomena , Hypothermia/complications , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...